LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

Search

Xenon Pharmaceuticals Inc

Cerrado

SectorSalud

38.79 1.62

Resumen

Variación precio

24h

Actual

Mínimo

37.92

Máximo

39.41

Métricas clave

By Trading Economics

Ingresos

-20M

-85M

Margen de beneficio

-867.293

Empleados

316

EBITDA

4.1M

-73M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+40.06% upside

Dividendos

By Dow Jones

Próximas Ganancias

11 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

299M

2.9B

Apertura anterior

37.17

Cierre anterior

38.79

Noticias sobre sentimiento de mercado

By Acuity

67%

33%

333 / 372 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Xenon Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

22 ago 2025, 23:09 UTC

Adquisiciones, fusiones, absorciones

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 4th Update

22 ago 2025, 22:02 UTC

Adquisiciones, fusiones, absorciones

Agreement Could Also Lead to Deeper Collaboration Between CSX, BNSF

22 ago 2025, 22:02 UTC

Adquisiciones, fusiones, absorciones

Some Analysts Say Agreement Suggests Lack of Confidence in Merger

22 ago 2025, 22:02 UTC

Adquisiciones, fusiones, absorciones

CSX, BNSF Intermodal Pact Draws Competing Views on Merger Possibility

22 ago 2025, 22:02 UTC

Adquisiciones, fusiones, absorciones

CSX, BNSF Pact Sparks Debate on Whether Another Rail Merger Is Approaching -- Analysis

22 ago 2025, 22:02 UTC

Adquisiciones, fusiones, absorciones

Pact Could Show Regulators That Transcontinental Service Can Come Without Merger

22 ago 2025, 21:23 UTC

Charlas de Mercado

Moody's Lowers Outlook on Austria to Negative From Stable -- Market Talk

22 ago 2025, 21:18 UTC

Charlas de Mercado

US Economic Growth Seen Slowing This Year -- Market Talk

22 ago 2025, 21:18 UTC

Adquisiciones, fusiones, absorciones

U.S. Takes 10% Stake in Intel -- Barrons.com

22 ago 2025, 21:03 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 ago 2025, 21:03 UTC

Charlas de Mercado

Mexican Stocks Close At Record High -- Market Talk

22 ago 2025, 20:58 UTC

Charlas de Mercado

US General Government Deficit Expected to Rise in 2026, 2027 -- Market Talk

22 ago 2025, 20:57 UTC

Adquisiciones, fusiones, absorciones

Intel: Government's Investment in Intel Will Be a Passive Ownership, With No Bd Representation or Other Governance or Info Rights >INTC

22 ago 2025, 20:57 UTC

Adquisiciones, fusiones, absorciones

Intel: Government Also Agrees to Vote With the Company's Bd of Directors on Matters Requiring Shareholder Approval, With Limited Exceptions >INTC

22 ago 2025, 20:57 UTC

Adquisiciones, fusiones, absorciones

Intel: Government Equity Stake Will Be Funded by Remaining $5.7B in Grants Previously Awarded, But Not Yet Paid, Under U.S. CHIPS and Science Act and $3.2B Awarded as Part of Secure Enclave Program >INTC

22 ago 2025, 20:57 UTC

Adquisiciones, fusiones, absorciones

Intel: Government Agrees to Purchase 433.3M Primary Shrs of Intel Common Stk at a Price of $20.47 per Shr, Equivalent to a 9.9% Stake in Co >INTC

22 ago 2025, 20:57 UTC

Adquisiciones, fusiones, absorciones

Intel: U.S. Government to Make $8.9B Investment in Intel Common Stk as Co Builds Upon Its More Than $100B Expansion of Resilient Semiconductor Supply Chain >INTC

22 ago 2025, 20:57 UTC

Adquisiciones, fusiones, absorciones

Intel: Intel and Trump Admin Reach Historic Agreement to Accelerate Amer Technology and Manufacturing Leadership

22 ago 2025, 20:56 UTC

Ganancias

These Stocks Moved the Most Today: Nvidia, Builders FirstSource, Zoom, Intuit, Workday, BJ's, Ubiquiti, and More -- Barrons.com

22 ago 2025, 20:55 UTC

Ganancias

These Stocks Are Moving the Most Today: Nvidia, Builders FirstSource, Zoom, Intuit, Workday, BJ's, Ubiquiti, and More -- Barrons.com

22 ago 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

22 ago 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Basic Materials Roundup: Market Talk

22 ago 2025, 20:41 UTC

Adquisiciones, fusiones, absorciones

U.S. Has 10% Stake in Intel, Lutnick Says -- Barrons.com

22 ago 2025, 20:24 UTC

Adquisiciones, fusiones, absorciones

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 3rd Update

22 ago 2025, 20:16 UTC

Adquisiciones, fusiones, absorciones

CSX and Warren Buffett's BNSF Made News. Why Investors Are Disappointed. -- Barrons.com

22 ago 2025, 19:19 UTC

Charlas de Mercado

Boeing to Restart Talks With Defense Workers' Union Monday -- Market Talk

22 ago 2025, 19:10 UTC

Charlas de Mercado

Oil Futures Gain as Russia-Ukraine Peace Seems Distant -- Market Talk

22 ago 2025, 19:06 UTC

Charlas de Mercado

U.S. Natural Gas Extends Losses as Summer Nears an End -- Market Talk

22 ago 2025, 19:03 UTC

Charlas de Mercado

Lower Borrowing Rates Elusive Even if Fed Cuts -- Market Talk

22 ago 2025, 18:52 UTC

Adquisiciones, fusiones, absorciones

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 2nd Update

Comparación entre iguales

Cambio de precio

Xenon Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

40.06% repunte

Estimación a 12 meses

Media 54.4 USD  40.06%

Máximo 65 USD

Mínimo 47 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Xenon Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

11

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

34.81 / 38.24Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

333 / 372 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.